Kyverna Therapeutics, Inc.
KYTX · NASDAQ
Company research
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical biopharmaceutical company headquartered in Emeryville, California, focused on developing cell therapies to liberate patients through the curative potential of CAR T-cell therapy for autoimmune diseases. The company's lead product candidate, mivocabtagene autoleucel (miv-cel, KYV-101), is an autologous CD19-targeting CAR T-cell therapy that has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases, with a recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis, as well as Phase 1/2 trials for lupus nephritis, multiple sclerosis, and systemic sclerosis. Beyond its lead asset, Kyverna is also advancing KYV-102, a next-generation autologous CD19 CAR T-cell candidate featuring whole blood rapid manufacturing, and KYV-201, an allogeneic CD19 CAR T-cell candidate developed in collaboration with Intellia Therapeutics, Inc. Founded in 2018 and publicly listed on NASDAQ since February 2024, Kyverna currently has a market capitalization of approximately $434 million and approximately 130 full-time employees.
Research reports
Danelfin’s AI-driven report assigns KYTX an AI Score of 6/10 (Hold), combining technical, fundamental, and sentiment signals to suggest a modest probability advantage over the market while emphasizing substantial volatility, negative cash flows, and mixed factor scores that warrant caution rather than an outright buy or sell stance.
Simply Wall St · June 22, 2026Kyverna Therapeutics (Nasdaq:KYTX) - Stock AnalysisSimply Wall St’s structured fundamental report sees KYTX as significantly undervalued, with revenue forecast to grow over 60% annually and analysts expecting the share price to more than triple, but highlights major risks including ongoing losses, minimal current revenue, shareholder dilution, and an absence of expected profitability over the next three years.
CirclFi · June 16, 2026Should You Buy Kyverna Therapeutics, Inc. Stock in 2026?CirclFi’s multi-model valuation piece assigns KYTX a low Quality of Company score and a composite fair value of 6.22 USD, below the then trading price, presenting bull and bear targets between 12.71 and 2.17 and stressing wide dispersion across 13 valuation models, elevated value-trap risk, and execution and manufacturing scale-up uncertainties that make the investment case highly assumption-dependent.
Investing.com (summarizing H.C. Wainwright) · June 3, 2026H.C. Wainwright reiterates Kyverna stock rating on autoimmune dataThis article reports H.C. Wainwright’s reiterated Buy rating and 25 USD price target on KYTX, citing Phase 1 rheumatoid arthritis data with meaningful reductions in disease activity, deep B-cell depletion, preserved vaccine immunity, and strong long-duration responses, alongside a rolling BLA for stiff person syndrome and strengthening of the finance and commercial leadership teams, pointing to substantial upside despite recent share volatility.
Investing.com (summarizing H.C. Wainwright) · April 22, 2026H.C. Wainwright reiterates Kyverna Therapeutics stock rating at buyInvesting.com summarizes H.C. Wainwright’s Buy rating and 20 USD target for KYTX, highlighting strong clinical data in stiff person syndrome and generalized myasthenia gravis with large functional improvements, durable responses and a favorable safety profile, plus a cash balance of roughly 279 million USD supporting runway into 2028, while acknowledging high cash burn and rapid share gains typical of clinical-stage biotech.
Blank Capital Research · March 1, 2026KYTX Analyst Report: Avoid Rating — March 2026Blank Capital’s quantitative factor-based report assigns KYTX an “Avoid” rating with a low composite score, emphasizing deeply negative profitability metrics, premium valuation relative to peers, high beta and short-interest indicators, and a thesis that the stock’s price implies aggressive growth and execution assumptions that are not sufficiently supported by current fundamentals.
Yahoo Finance · December 18, 2025Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class ProspectsThis Yahoo Finance valuation article argues that positive KYSA-8 trial data and the possibility of a first-in-class autoimmune CAR T approval position KYTX attractively at around two times book value, noting strong recent share-price momentum and perceived undervaluation versus peers while highlighting key risks around follow-up data, regulatory outcomes, and CAR T safety that could materially impact the valuation.